US 11566076
Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 11566076 (Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers) held by Five Prime Therapeutics, Inc. expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 25
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/54, A61K2039/545